Immodulon Announces Formation of New Scientific Advisory Board to Support Late-stage Clinical Development of IMM-101

by John Bachtiger | 12th December 2023 | Press Releases

Professor Dr. med. Thomas Seufferlein appointed Chair of new Scientific Advisory Board (SAB) composed of leaders with deep expertise in the clinical oncology field New SAB to complement significant oncology drug development experience of Immodulon’s new management...

Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer

by uimmodulon_admin | 26th June 2023 | Press Releases

Richard Couch, formerly at Celgene, appointed as Chief Technology Officer Owen Vaughan, formerly at Taiho Oncology, appointed as Chief Regulatory Officer Appointments add decades of industry experience to support advancement of IMM-101 into a pivotal trial in...

Immodulon Appoints Experienced Clinical and Medical Affairs Executive Josefine Roemmler-Zehrer, MD, Associate Professor, as Chief Medical Officer

by Sandi Greenwood | 5th June 2023 | Press Releases

Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertise Adding further oncology experience to Immodulon’s leadership team as the company prepares to advance IMM-101 into a pivotal trial in...

Immodulon Appoints New Chair and Leadership Team to Drive Late-Stage Clinical Development of IMM-101 in Pancreatic Cancer

by Sandi Greenwood | 10th May 2023 | Press Releases

Richard Davies, Deputy Chairman of Alvotech, elected as Chairman of the Board Gertjan Bartlema, formerly at Celgene and Amgen, appointed as Chief Executive Officer Peter Greaney, formerly at ADC Therapeutics and Celgene, appointed as Chief Business Officer...

Immodulon strengthens Board of Directors with two industry veteran appointments

by uimmodulon_admin | 14th June 2022 | Press Releases

Seasoned global biopharmaceutical executives add significant clinical and commercial experience to Immodulon Dr. Selwyn Ho and Gertjan Bartlema will join the Board with immediate effect Uxbridge, UK – 14 June 2022 – Immodulon Therapeutics Limited, the immuno-oncology...

Immodulon presents Phase II clinical data of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

by uimmodulon_admin | 7th June 2022 | Press Releases

IMM-101 in combination with nivolumab was well-tolerated and demonstrated encouraging efficacy data Primary endpoints were met, including 73% Overall Response Rate (ORR) in treatment-naïve patients with advanced melanoma Uxbridge, UK, 7 June 2022 – Immodulon...